期刊文献+

小鼠NGF基因治疗型DNA质粒的构建及中试工艺的优化 被引量:1

Construction of Therapeutic Mouse NGF DNA Plasmid and Optimization of Procedure for Pilot Production
下载PDF
导出
摘要 目的构建小鼠NGF基因治疗型DNA质粒,并进行中试工艺的优化。方法用SignalP3.0 Server软件选择并设计与NGF融合的信号肽;根据哺乳动物密码子偏爱性,对小鼠NGF的编码序列进行优化;通过流加补料等方式优化中试生产工艺;体外瞬时转染测定DNA质粒的表达和体外生物学活性。结果所构建的含有IgG/ngf的重组质粒,通过中试规模的发酵和纯化,获得了大量的高纯度重组质粒,该重组质粒可以在体外表达出具有生物学活性的NGF。结论构建了具有与小鼠NGF相似的生物学活性的重组质粒,并建立了中试生产工艺。 Objective To construct a therapeutic mouse NGF DNA plasmid and optimize the procedure for pilot production of the plasmid.Methods The signal peptide fusing with mouse NGF was selected and designed by SignalP3.0 Server software. The ORF of fusion protein containing mouse NGF and signal peptide was optimized according to mammalian genetic coden bias. The pilotproduction procedure was optimized by fed-batch.The expression and biological activity in vitro of NGF DNA plasmid were analyzed by in vitro transient transfection-chick embryo dorsal root nerve ganglion culture. Results The recombinant plasmid containing IgG/ngf was successfully constructed and prepared in a large quantity by pilot fermentation and purification. The NGF with biological activity was expressed in vitro by using the constructed recombinant plasmid. Conclusion The constructed recombinant plasmid showed similar biological activity with that of mouse NGF,and a pilot production procedure was developed.
出处 《中国生物制品学杂志》 CAS CSCD 2008年第3期216-220,230,共6页 Chinese Journal of Biologicals
关键词 神经生长因子 DNA质粒 生物学活性 中试工艺 Nerve growth factor DNA plasmid Biological activity Pilot procedure
  • 相关文献

参考文献4

  • 1Costantini C,Scrable H,Puglielli L.An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation. EMBO J,2006,25(9) : 1997-2006.
  • 2Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine, 2007,25 ( 19 ) : 3731-3741.
  • 3Aurikko JP, Ruotolo BT, Grossmann JG, et al. Characterization of symmetric complexes of nerve growth factor and the ectodomain of the panneurotrophin receptor, p75^NTR. J Biol Chem, 2005, 280(39): 33453- 33460.
  • 4Fredriksen AB, Sandlie I, Bogen B. DNA vaccine increase immunogenicity of idiotypic tamor antigen by targeting novel fusion proteins to antigenpresenting cells. Mot Ther,2006,13(4) :776-785.

同被引文献2

  • 1Costantini C, Scrable H, Puglielli L. An aging pathway controls the TrkA to p75NTR receptor switch and amyloid beta-peptide generation. EMBO J, 2006, 25(9): 1997-2006.
  • 2ICH指导委员会.药品注册的国际技术要求(质量部分).周海钧.主译.北京:人民卫生出版社,2007.

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部